The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy

被引:0
|
作者
Mennini, Francesco S. [1 ]
Scortichini, Matteo [1 ]
Colivicchi, Furio [2 ]
Maggioni, Aldo P. [3 ]
Sciattella, Paolo [1 ]
机构
[1] Univ Roma Tor Vergata, Fac Econ, Ctr Econ & Int Studies, Econ Evaluat & Hlth Technol Assessment, Via Columbia 2, I-00133 Rome, Italy
[2] San Filippo Neri Hosp, Div Cardiol, Rome, Italy
[3] ANMCO Res Ctr Heart Care Fdn, Florence, Italy
关键词
STATIN THERAPY; EZETIMIBE; RISK; ASSOCIATION; ADHERENCE; EFFICACY;
D O I
10.1007/s40261-024-01365-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundAtherosclerotic cardiovascular diseases remain the primary cause of mortality in Italy. Individuals with a history of acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack face an elevated risk of recurrent major adverse cardiovascular events, including mortality. The population aging, coupled with increasing risk factors such as diabetes mellitus and obesity, exacerbates the disease's economic impact.ObjectivesThis study aims to comprehensively assess the economic burden of atherosclerotic cardiovascular diseases in Italy, specifically focusing on direct healthcare costs.MethodsWe analyzed real-world data from administrative databases in the Marche region and Local Health Unit Umbria 2. The economic burden of patients discharged with acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack was evaluated, with a focus on direct costs associated with hospitalizations, drugs, and outpatient visits. Results were stratified by age, sex, comorbidities at baseline, and adherence to lipid-lowering therapy and antihypertensive agents.ResultsAnnually, nearly 350,000 patients were hospitalized for peripheral arterial disease, acute coronary syndrome, or ischemic stroke/transient ischemic attack. Direct health costs averaged <euro>7190 per patient over a 2-year follow-up, with hospitalizations accounting for nearly 70% of the total. Male patients incurred significantly higher costs (<euro>7467) than female patients (<euro>6625). Costs correlated positively with age and with the number of baseline comorbidities, with a range from <euro>5259 (0-1 comorbidities) to <euro>17,095 (4+ comorbidities). Costs were significantly lower in adherent subjects (<euro>6813) compared with non-adherent subjects (<euro>7757).ConclusionsThis study provides valuable insights into the economic implications of atherosclerotic cardiovascular diseases in Italy, emphasizing the necessity of a comprehensive approach to preventive measures, optimal medication adherence, and lifestyle modifications to mitigate its impact.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] ECONOMIC BURDEN OF DIABETIC PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Marcellusi, A.
    Sciattella, P.
    Bini, C.
    Rotundo, M.
    Aimaretti, G.
    Mennini, F. S.
    [J]. VALUE IN HEALTH, 2020, 23 : S509 - S509
  • [2] ECONOMIC BURDEN OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND SPECIFIC EVENTS IN ONTARIO, CANADA
    Rogoza, R.
    Oh, P.
    Goodman, S. G.
    Fairbairn, M.
    Packalen, M.
    Motsepe-Ditshego, P.
    Pericleous, L.
    Goeree, R.
    [J]. VALUE IN HEALTH, 2020, 23 : S96 - S96
  • [3] Osteoporosis: Economic Burden of Disease in Italy
    Andrea Marcellusi
    Maria Assunta Rotundo
    Claudia Nardone
    Paolo Sciattella
    Simone Gazzillo
    Maurizio Rossini
    Mario Barbagallo
    Amalia Antenori
    Domenico Valle
    Francesco Saverio Mennini
    [J]. Clinical Drug Investigation, 2020, 40 : 449 - 458
  • [4] Osteoporosis: Economic Burden of Disease in Italy
    Marcellusi, Andrea
    Rotundo, Maria Assunta
    Nardone, Claudia
    Sciattella, Paolo
    Gazzillo, Simone
    Rossini, Maurizio
    Barbagallo, Mario
    Antenori, Amalia
    Valle, Domenico
    Mennini, Francesco Saverio
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (05) : 449 - 458
  • [5] The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy
    Case, Brian C.
    Bress, Adam P.
    Kolm, Paul
    Philip, Sephy
    Herrick, Jennifer S.
    Granowitz, Craig B.
    Toth, Peter P.
    Fan, Wenjun
    Wong, Nathan D.
    Hull, Michael
    Weintraub, William S.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 754 - 761
  • [6] PREVALENCE AND BURDEN OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Kandlakunta, Harika
    Patlolla, Sri Harsha
    Kandlakunta, Sriharsha
    Chalhoub, Jean M.
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S911 - S911
  • [7] Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
    Carlsson, Katarina Steen
    Faurby, Mads
    Nilsson, Kristoffer
    Wolden, Michael Lyng
    [J]. DIABETES THERAPY, 2023, 14 (08) : 1357 - 1372
  • [8] Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
    Katarina Steen Carlsson
    Mads Faurby
    Kristoffer Nilsson
    Michael Lyng Wolden
    [J]. Diabetes Therapy, 2023, 14 : 1357 - 1372
  • [9] Economic Burden of Cardiovascular Disease in the Southwest of Iran
    Emamgholipour, Sara
    Sari, Ali Akbari
    Pakdaman, Mohsen
    Geravandi, Sara
    [J]. INTERNATIONAL CARDIOVASCULAR RESEARCH JOURNAL, 2018, 12 (01) : 1 - 6
  • [10] Economic burden of cardiovascular disease in the Russian Federation
    Oganov, R. G.
    Kontsevaya, A. V.
    Kalinina, A. M.
    [J]. CARDIOVASCULAR THERAPY AND PREVENTION, 2011, 10 (04): : 4 - 9